MARKET

ICLR

ICLR

ICON PLC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

227.30
+9.66
+4.44%
After Hours: 227.30 0 0.00% 16:00 05/27 EDT
OPEN
219.90
PREV CLOSE
217.64
HIGH
228.25
LOW
219.53
VOLUME
415.28K
TURNOVER
0
52 WEEK HIGH
313.00
52 WEEK LOW
199.01
MARKET CAP
18.48B
P/E (TTM)
91.16
1D
5D
1M
3M
1Y
5Y
4 Analysts Have This to Say About Icon
Analysts have provided the following ratings for Icon (NASDAQ:ICLR) within the last quarter:
Benzinga · 4d ago
Guggenheim Starts ICON at Buy With $285 Price Target
MT Newswires · 4d ago
ICON plc to present at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference
DUBLIN, May 23, 2022--ICON plc to present at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference
Business Wire · 5d ago
ICON Named Business & Finance Company of the Year and One of Forbes’ Best Employers for Diversity
DUBLIN, May 23, 2022--ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, has been recognised with a number of prestigious ...
Business Wire · 5d ago
The five-year decline in earnings might be taking its toll on ICON (NASDAQ:ICLR) shareholders as stock falls 8.5% over the past week
While ICON Public Limited Company ( NASDAQ:ICLR ) shareholders are probably generally happy, the stock hasn't had...
Simply Wall St. · 05/10 16:49
ICON plc to present at the BofA Securities 2022 Healthcare Conference
DUBLIN, May 03, 2022--ICON plc to present at the BofA Securities 2022 Healthcare Conference
Business Wire · 05/03 20:15
Research Alert: CFRA Keeps Hold Opinion On Shares Of Icon Public Limited Company
MT Newswires · 05/03 00:23
Icon PLC (ICLR) Q1 Earnings and Revenues Beat Estimates
Icon PLC (ICLR) delivered earnings and revenue surprises of 1.85% and 1.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/27 22:35
More
No Data
Learn about the latest financial forecast of ICLR. Analyze the recent business situations of ICON PLC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

26.67%Strong Buy
33.33%Buy
40.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ICLR stock price target is 275.82 with a high estimate of 315.00 and a low estimate of 250.00.
High315.00
Average275.82
Low250.00
Current 227.30
EPS
Actual
Estimate
0.711.412.112.82
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 688
Institutional Holdings: 83.27M
% Owned: 102.44%
Shares Outstanding: 81.29M
TypeInstitutionsShares
Increased
188
5.44M
New
86
667.10K
Decreased
173
5.09M
Sold Out
52
1.23M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Ciaran Murray
Chief Financial Officer/IR Contact Officer
Brendan Brennan
Executive Vice President/Chief Administrative Officer/General Counsel/Secretary
Diarmaid Cunningham
Lead Director/Independent Director
Ronan Murphy
Director
Linda Grais
Director
Colin Shannon
Independent Director
Hugh Brady
Independent Director
John Climax
Independent Director
Joan Garahy
Independent Director
William Hall
Independent Director
Eugene McCague
Independent Director
Julie O'Neill
Independent Director
Mary Pendergast
No Data
No Data
About ICLR
ICON Public Limited Company is a clinical research organisation (CRO). The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. The Company specialises in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. It conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The Company offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.

Webull offers kinds of ICON PLC stock information, including NASDAQ:ICLR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICLR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICLR stock methods without spending real money on the virtual paper trading platform.